Beth Israel Deaconess Medical Center 330 Brookline Ave; HM-1049
Boston, MA 02215
Advanced Degree And Training Info:
Year
Institution
Area or Rank
No data available
Research Team Listing
No team members listed
Areas of Interest:
Cancer & Hematologic
Patient Oriented / Translational
Major Research Theme:
We have a multi-discipline translational group focused on prostate cancer. Dr. Balk is responsible for the basic research portion of our group activities and I am responsible for the clinical research activities. However, Dr. Balk has clinical interests and I have basic research interests. I am approximately 70% clinically based with approximately 200 outpt visits per month. Included in our clinical group are Stephen Duggan, Mary Ellen Morrissey, Kristen Rada, Cesar Vazquez and Steven Balk, Rupal Bhatt, and Marc Garnick. My interst is in newer targeted therapy for prostate cancer including targeting the PI3K/mTOR pathway for treatment of refractory prostate cancer.
George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, DeWolf WC, Kantoff PW, Bubley GJ. Radical Prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urol. 63:327-332, 2004
George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, DeWolf WC, Kantoff PW, Bubley GJ. Radical Prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urol. 63:327-332, 2004
George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, DeWolf WC, Kantoff PW, Bubley GJ. Radical Prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urol. 63:327-332, 2004
Bhatt RS, Landis DM, Zimmer M. Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ. Hypoxia inducible factor alpha : effect on radiaiton sensitivity and differential regulation by an mTOR inhibitor Brit Journal of Urol 101:1084-1089, 2008
Maseillo D, Mohi MG, McKnight N, Smith Bm Neel BG, Balk, SP, BUbley GJ. COmbining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer BIol THer 6:195-201, 2007
Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. A prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent
prostate cancer. J Clin Oncol. 18:3705-3712, 2004
Ko Y-J, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ. A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone refractory prostate cancer. Clin. Cancer Res. 2001;7:800-805.
Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP ANdrogen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1 Proc Natl Acad Sci USA 103:15969-16974, 2006
External Recognition:
DFCI SRC
Director of GU ONC BIDMC
National Co Chair of Inter Prostate Cancer Spore COmmittee for Clinical Research in Prostate Cancer
Co PI of DF/HCC Prostate Cancer SPORE program
